🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,068 results for “Pharm” Clear

  1. ACICLOVIR VIATRIS 500 mg, poudre pour solution injectable (I.V.), CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  2. ACIDE FOLIQUE CCD 5 mg, comprimé, PLACEBO D'ASPIRINE PROTECT, ASPIRINE PROTECT 100 mg, comprimé gastro-résistant, PLACEBO D'ACIDE FOLIQUE

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  3. ACP-204

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 3 small molecule active

    2 trials

  4. ACP-204

    Acadia Pharmaceuticals B.V.

    Lewy Body Dementia Psychosis

    phase 3 small molecule active

    2 trials

  5. ACR16

    Teva Pharma GmbH

    Huntington's Disease

    phase 3 small molecule completed

    1 trial

  6. ACTILYSE 50mg placebo, ACTILYSE, poudre et solvant pour solution injectable et perfusion

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  7. ACTIQ (Oral transmucosal fentanyl citrate)

    Teva Pharma GmbH

    Breakthrough Pain

    phase 3 small molecule completed

    1 trial

  8. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  9. AD04 (ondansetron)

    ADIAL PHARMACEUTICALS, INC.

    Alcohol Use Disorder

    phase 3 small molecule completed

    1 trial

  10. ADSTILADRIN

    Ferring Pharmaceuticals A/S

    Intermediate risk, non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  11. ADVATE 500 IU powder and solvent for solution for injection., VEYVONDI 1300 IU powder and solvent for solution for injection., ADVATE 1000 IU powder and solvent for solution for injection., VEYVONDI 650 IU powder and solvent for solution for injection.

    Takeda Pharmaceuticals International AG

    severe von Willebrand Disease

    phase 3 small molecule active

    1 trial

  12. ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680, ALKS 2680

    Alkermes Pharma Ireland

    Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

    phase 3 small molecule active

    1 trial

  13. ALPELISIB, ALPELISIB, ALPELISIB

    Cancer Prevention Pharma (Ireland) Limited

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  14. ALX1-11

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  15. ALX1-11 (drug)

    Takeda Pharmaceuticals International AG

    Osteoporosis

    phase 3 small molecule completed

    1 trial

  16. AMG 479

    Takeda Pharmaceuticals International AG

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  17. AMG 706

    Takeda Pharmaceuticals International AG

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  18. AMIKACIN

    Pari Pharma GmbH

    Adult patients admitted to intensive care

    phase 3 small molecule active

    1 trial

  19. AMOXICILLIN TRIHYDRATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM , LEVOFLOXACIN, AMOXICILLIN , AZITHROMYCIN, AZITHROMYCIN , IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., LEVOFLOXACIN

    Pari Pharma GmbH

    Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

    phase 3 small molecule active

    1 trial

  20. AMOXICILLINE/ACIDE CLAVULANIQUE PANPHARMA 2 g/200 mg ADULTES, poudre pour solution injectable

    Pari Pharma GmbH

    Intensive care, Ventilator Associated Pneumonia

    phase 3 small molecule active

    1 trial

  21. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    5 trials

  22. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Progressive Supranuclear Palsy

    phase 3 small molecule completed

    1 trial

  23. AMX0035, PL1 Oral powder in sachet, oral use

    Pharma Mar S.A.

    Amyotrophic Lateral Sclerosis (ALS)

    phase 3 small molecule active

    1 trial

  24. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Cancer Prevention Pharma (Ireland) Limited

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources